By Nurse Mark
Dr. Myatt is very successful in her treatment of patients with rheumatoid arthritis – and she stays on the cutting edge when it comes to news about drugs and therapies for this disease that conventional medicine finds so challenging. Many of her patients come to her debilitated by conventional, poorly-proven, and toxic drug therapies. Such was the case with one patient to whom she sent the following information. Fortunately, as a result of Dr. Myatt’s treatment this fellow is no longer using the Humira drug that the FDA has been forced to warn doctors about.
May 29, 2009
The US Food and Drug Administration (FDA) has issued a reminder on the risk for serious fungal infections associated with all tumor necrosis factor-alpha (TNF-alpha) inhibitors, including golimumab (Simponi, Centocor Ortho-Biotech Inc).
Golimumab is a new TNF-alpha blocker approved by the FDA for the treatment of adult patients with moderate to severe rheumatoid arthritis.
The reminder was issued because " histoplasmosis and other invasive fungal infections are not consistently recognized in patients taking TNF- blockers including Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab)."
This lack of recognition "has resulted in delays in appropriate antifungal treatment, sometimes even resulting in death," according to an alert sent today by MedWatch, the FDA’s safety information and adverse event reporting program.
As previously reported by Medscape Medical News , the FDA ordered makers of TNF-alpha inhibitors to strengthen warnings regarding the risk for histoplasmosis and other invasive fungal infections on September 4, 2008.
Yikes! What manner of poisons are we being fed in the Big Pharma quest for profit? How do they get away with this sort of thing?!?
Posted in Drugs and Alternatives | No Comments »